2019
Sacubitril/Valsartan Initiated in Black Patients Admitted for Acute Decompensated Heart Failure Reduced NT-proBNP, was Safe and Led to Improved Clinical Outcomes- A Secondary Analysis of the PIONEER-HF Trial
Velazquez E, Ambrosy A, Morrow D, McCague K, Duffy C, O'Brien T, Rocha R, DeVore A, Braunwald E. Sacubitril/Valsartan Initiated in Black Patients Admitted for Acute Decompensated Heart Failure Reduced NT-proBNP, was Safe and Led to Improved Clinical Outcomes- A Secondary Analysis of the PIONEER-HF Trial. Journal Of Cardiac Failure 2019, 25: s80. DOI: 10.1016/j.cardfail.2019.07.227.Peer-Reviewed Original ResearchAcute decompensated HFPIONEER-HF trialHeart failureNT-proBNPBlack patientsPg/mLAngioedema eventsHospital initiationClinical outcomesAcute decompensated heart failureAngiotensin receptor neprilysin inhibitorPre-specified subgroup analysisPrior heart failureACEI/ARBDecompensated heart failureNatriuretic peptide levelsSacubitril/valsartanImproved clinical outcomesSelf-reported raceCV deathEnalapril armHemodynamic stabilizationSymptomatic hypotensionRenal functionNeprilysin inhibitor
2006
Previously known and newly diagnosed atrial fibrillation: A major risk indicator after a myocardial infarction complicated by heart failure or left ventricular dysfunction☆
Køber L, Swedberg K, McMurray JJ, Pfeffer MA, Velazquez EJ, Diaz R, Maggioni AP, Mareev V, Opolski G, Van de Werf F, Zannad F, Ertl G, Solomon SD, Zelenkofske S, Rouleau J, Leimberger JD, Califf RM. Previously known and newly diagnosed atrial fibrillation: A major risk indicator after a myocardial infarction complicated by heart failure or left ventricular dysfunction☆. European Journal Of Heart Failure 2006, 8: 591-598. PMID: 16507350, DOI: 10.1016/j.ejheart.2005.11.007.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAgedAngiotensin II Type 1 Receptor BlockersAtrial FibrillationCaptoprilCardiac Output, LowFemaleHumansMaleMiddle AgedMyocardial InfarctionOutcome Assessment, Health CarePrognosisProportional Hazards ModelsRisk AssessmentRisk FactorsSurvival AnalysisTetrazolesTime FactorsValineValsartanVentricular Dysfunction, LeftConceptsAcute myocardial infarctionCurrent atrial fibrillationPrior atrial fibrillationHeart failureAtrial fibrillationRisk of deathMyocardial infarctionCV eventsGreater long-term mortalityMajor CV eventsPrior heart failureAdverse CV eventsMajor cardiovascular eventsVentricular systolic dysfunctionLong-term mortalityHR of deathMajor risk indicatorsCardiovascular eventsSystolic dysfunctionVentricular dysfunctionPrimary outcomeVALIANT trialPatientsLVSDInfarction
2005
Heart failure on admission and the risk of stroke following acute myocardial infarction: the VALIANT registry
Szummer KE, Solomon SD, Velazquez EJ, Kilaru R, McMurray J, Rouleau JL, Mahaffey KW, Maggioni AP, Califf RM, Pfeffer MA, White HD. Heart failure on admission and the risk of stroke following acute myocardial infarction: the VALIANT registry. European Heart Journal 2005, 26: 2114-2119. PMID: 15972293, DOI: 10.1093/eurheartj/ehi352.Peer-Reviewed Original ResearchConceptsRisk of strokeHeart failureAcute myocardial infarctionMyocardial infarctionHospital strokeStroke riskOdds ratioAcute Myocardial Infarction RegistryPresence of HFConsecutive MI patientsKillip class IIIPrior heart failureHistory of hypertensionHistory of strokeMyocardial Infarction RegistryHospital mortalityKillip classBaseline characteristicsDismal prognosisMI patientsRisk factorsPatientsAdmissionClass IIIStroke